Introduction
Peritonealcarcinomatosis(PC)isacommoneventinpatients withgastrointestinal(GI)cancerandisassociatedwithpoor survival and deteriorating quality of life [1] [2] [3] . Systemic chemo therapy has shown minimal efficacy [4, 5] . Only selected patients with small-volume PC benefit from peritonectomy plus intraoperative intraperitoneal chemotherapy [6, 7] .Currently,thereisnoeffectivetreatmentforthemajorityofpatientswithadvancedPC.
Catumaxomab (anti-EpCAM × anti-CD3) (Removab ® , Fresenius Biotech GmbH, Munich, Germany) is a trifunctional antibody that binds the epithelial cell adhesion molecule (EpCAM) on tumor cells and CD3 on T lymphocytes. ItsintactFcregion,whichiscomposedof2potentimmuno-globulin (Ig) isotypes (mouse IgG 2a and rat IgG 2b ), binds to type I and III Fcg receptors on accessory cells, including monocytes, macrophages, and dendritic cells [8, 9] . These specificitiesinduceeffectivetumorcellkilling [10, 11] ,which wasrecentlydemonstratedinpatientswithmalignantascites [12] [13] [14] . EpCAMisoverexpressedintumorcellsofmorethan90% of patients with GI cancer [15] . Although EpCAM is expressed on normal epithelial tissues, it is specific for tumor cells in the peritoneal cavity because peritoneal cells are of mesothelialoriginandthereforedonotexpressEpCAM.In addition,Tlymphocytesandaccessorycellsarepresentinthe peritonealcavity [16] .Thus,intraperitonealadministrationof catumaxomab provides the advantage of targeted immunotherapyforperitonealtumorcells.Basedonthisrationaleand the convincing results in patients with malignant ascites [12, 13] ,thisstudyinvestigatedtheeffectsofintraperitonealcatumaxomab therapy in patients with non-ascites-accumulating and non-resectable PC from colon, gastric, or pancreatic cancer.
Patients and Methods

Patients
Patients aged ≥ 18 years with an immunohistochemical diagnosis of EpCAM-positive PC from gastric, colorectal, or pancreatic cancer and withaKarnofskyperformancestatus(KPS)≥60%wereeligible.Exclusion criteria were: prior exposure to mouse monoclonal antibodies or treatmentwithanyinvestigationaldrugwithintheprevious30days;inadequateorgan,immunologic,orendocrinefunction;uncontrolledacuteor chronicinfection;chronicsteroidtherapy;historyofsevereallergicreactionandascites>1000mlwithintheprevious30days.Writteninformed consent was obtained from all patients. The protocol was approved by independentethicscommitteesandthestudywasconductedaccordingto theDeclarationofHelsinkiandGoodClinicalPracticeguidelines.
Study Design
Thiswasanopen-label,multicenter,three-part,phaseI/IIclinicaltrialto evaluatetolerabilityandsafety,todeterminethemaximaltolerateddose (MTD)andtoobtainpreliminaryevidenceofclinicalefficacyforintraperitonealtreatmentwithcatumaxomabinpatientswithPC.Toconfirm EpCAM-positive PC, a tumor sample was collected during laparoscopy or laparotomy 7 days before treatment and analyzed histochemically. Aportsystemwasimplantedtoensuresafeinfusionsintotheperitoneal cavity. Homogenous distribution was controlled by computed tomography (CT) scans after intraperitoneal administration of 2000 ml of balancedelectrolytesolutionwithcontrastmedium.
Catumaxomab was manufactured by TRION Pharma, Munich, Germany/Fresenius Biotech, Munich, Germany. In part 1 of the study, patients received 4 6-h intraperitoneal infusions of catumaxomab togetherwith1000mlelectrolytesolution,toensurehomogeneousdistribution.Adelayofupto4daysforeachinfusionwasallowed.Premedicationconsistedoforalacetaminophen(1000mg).Thedoselevelsforthe infusions were composed according to a dynamic escalation schedule asfollows-day0:10mg;day3:10or20mg;day7:30,50,or100mg;and day 10: 50, 100, or 200 mg, which was based on former studies [12, 17] . Doseescalationwasguidedbytheoccurrenceofdose-limitingtoxicities (DLTs):TheMTDwasdeterminedseparatelyforthefirst,second,third, and fourth infusion. If none of 3 patients experienced DLTs, the next dose level for the first, second, third, and fourth infusion was implemented.Ifoneof3patientsexperiencedDLTs,afurther3patientswere investigatedatthatdoselevel.Ifnoneoftheadditional3patientsexperi-enced DLTs, subsequent patients received the next highest dose schedule. If 2 or more of 2-6 patients experienced DLTs, the dose-steering board(DSB)definedtheMTD.Inpart2ofthestudy,theprotocolwas amendedinordertoinvestigateashorteradministrationperiodof3hat theMTDinanother6patients.Inpart3,patientsreceived3-hintraperitonealinfusionsofcatumaxomabatdoseshigherthantheMTDtogether withdexamethasone10mg.
Assessments
Toxicityandvitalsignswereassesseddaily.Humananti-mouseantibody (HAMA) titers were measured to investigate the immunogenicity of catumaxomab.Otherimmunologicmarkersincludedinterleukin-6(IL-6) and tumor necrosis factor-alpha (TNF-a). PC burden was staged using theclassificationofGillyetal.(stages0-IV;stageI:malignantgranulations<5mmingreatestdimension,localizedinonepartoftheabdomen; stageII:malignantgranulations<5mm,diffusetothewholeabdomen; stageIII:malignantgranulations5-2cm;stageIV:largemalignantcakes (> 2 cm) [18] . Peritoneal lavages were examined for EpCAM-positive tumor cells using immunohistochemistry at the start and end of treatment.ToxicitywasgradedusingtheNationalCancerInstituteCommon Toxicity Criteria (NCI-CTC, version 2.0, 1999). Adverse events were codedusingtheMedicalDictionaryforRegulatoryActivities(MedDRA) andtabulatedbydosegroupandtimeoffirstappearance,todetermine theincidenceofadverseevents,treatment-relatedadverseeventswitha definite, probable, possible, or non-assessable relationship to the study drug,andadverseeventsofNCI-CTCgrade≥3orthoseleadingtotreat-mentdiscontinuation.ADLTwasdefinedasanyadverseeventgrade≥3 that caused interruption of catumaxomab infusion and could not be relievedbystandardtherapeuticmeasures,oranylaboratoryabnormality grade ≥ 3 that failed to show a significant trend toward normal within 96 h, or any other condition considered critical to the patient's health. Tumor assessments in patients with measurable disease were made accordingtotheResponseEvaluationCriteriainSolidTumors(RECIST) [19] byCTscans1monthafterthestartoftreatment.Thesurvivalstatus ofpatientswasassessedevery3months.
Statistical Analysis
All study parameters were analyzed descriptively. After the end of the study, a post-hoc, matched-pair analysis was performed to compare the survivalofpatientswiththatofacontrolgroupofpatientswhoreceived conventionalintravenouschemotherapy.Thematchedpatientswereselectedfrom217PCpatientstreatedbetween2002and2005.Formatching purposes,onlypatientswithadequategeneralconditionwhowereableto receive conventional intravenous chemotherapy after diagnosis of PC wereconsideredinordertopreventselectionbiasfavoringPCpatients with poor clinical condition and survival. Patients receiving immunotherapywereexcluded.Matchingvariableswereprimarytumorsiteand extentofPCaccordingtotheclassificationofGillyetal. [18] .Sex,age, and incidence of distant metastasis were also considered for matching. Overallsurvival(OS)wasdefinedasthetimefromthefirstdiagnosisof PC until death or last follow-up. Kaplan-Meier curves were calculated andthecomparisonwasbasedonalog-ranktest.
Results
Between2003and2005,24patientswereenrolled.Mostpatientswerepreviouslytreatedwithsurgeryandchemotherapy and all but 2 patients had advanced Gilly stage III/IV PC. MeantimefromfirstdiagnosisofPCtostartofcatumaxomab treatment was 113 days (median 79.5, range 7-347 days) (table1). PeritonealcarcinomatosisstagingaccordingtoGillyetal. [18] :stageI: malignant granulations < 5 mm in greatest dimension, localized in one partoftheabdomen;stageII:malignantgranulations<5mm,diffuseto thewholeabdomen;stageIII:malignantgranulations5-2cm;stageIV: largemalignantcakes(>2cm). 
Safety
The 12 patients who received catumaxomab at the MTD, eitherasa6-h(5patients)ora3-hinfusion(7patients),constituted the safety population. A total of 121 adverse events and95treatment-relatedadverseeventswerereported.Each patient experienced at least 1 treatment-related adverse event.Themajorityoftreatment-relatedadverseeventswere mild or moderate; only 13 events affecting 6 patients were NCI-CTC grade 3. No grade 4 treatment-related adverse events and no drug-related deaths occurred. The most common treatment-related adverse events were fever, vomiting, abdominalpain,skintoxicity,andnausea(table3).Feverwas the most common treatment-related adverse event (16 episodesin8patients).Therewasnosubstantialdifferenceinthe incidence of treatment-related adverse events between the 6-h and 3-h infusions. 9 of 12 patients (75%) treated at the MTD experienced grade 3 elevations of liver function tests (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyltransferase, alkaline phosphatase, and bilirubin). No significant abnormalities in urinalysis occurred. Theoverallmeansofhemoglobin,redbloodcellcount,and plateletcountremainedalmostconstant.Thetotalwhitecell and neutrophil counts markedly increased while the lymphocyte count transiently decreased after each infusion. Grade 3 lymphopenia developed in 10 patients (83%). All grade3hematologicabnormalitiesimprovedtograde0-2at thefinalexamination(about14daysafterthelastinfusion). PlasmalevelsofIL-6rangedfrom1.6to134pg/mlatbaselineandpeakedthedayaftereachinfusion.ThehighestIL-6 levels were observed after the first infusion, exceeding the baselinelevelmorethan1000-fold(maximum:15,308pg/ml). TNF-aplasmalevelsvariedfrom<15to46pg/mlatbaseline and also increased after the infusions. Peak values were reachedafterthethirdandfourthinfusion(>1000pg/mlin3 patients; fig.1 ).HAMAswerenotdetectableintheserumof any patients at the baseline evaluation. Among 11 patients withavailabledata,theHAMAlevelchangedfromnegative topositivein7patients.HAMAtitersrangedfrom35×10 6 to 520×10 6 ng/ml(median71.0×10 3 ng/ml).Therewasnoclear relationship between elevated HAMA titers and adverse events.
Clinical Efficacy
17 of 24 patients were evaluable for response according to RECIST criteria. 11 of 17 (65%) patients were progression free 1 month after the start of treatment. Responses were seenacrossalldoselevels:1patienthadcompleteremission, 3 patients had partial remission, and 7 patients had stable disease(table4).Peritoneallavagesamplesatbaselineandat dischargewereobtainedfrom10patients.NoEpCAM-positivetumorcellsweredetectableateitherexaminationin1pa-tient, the number decreased in 6 patients and increased slightly in 3 patients. The most dramatic therapeutic effect was seen in a patient treated at the MTD whose number of EpCAM-positiveperitonealcellsdecreasedfrom87,105to39 per10 6 cells( fig.2 ). MedianOSforallpatients(table4)fromthestartoftreatmentwas273days(9.1months).MedianOSfromfirstdiagnosis of PC was 502 days (16.7 months). 10 of 24 patients received chemotherapy after treatment with catumaxomab. Interestingly, no patient had tumor progression in terms of newlydiagnosedmalignantascitesduringfollow-up.Sincedecreasing numbers of EpCAM-positive tumor cells in peritoneallavagesandclinicalresponsesindicatedtherapeuticefficacy, a matched-pair analysis of OS was performed. The matchedcontrolgroupwasidenticaltothegroupofstudypatientsintermsofprimarytumorsiteandextentofPCaccording to the classification of Gilly et al. [18] : The mean Gilly scorewas3.3inbothgroups.Therewasnosignificantdifference in age, sex, and incidence of distant metastasis. As requiredbymatchingcriteria,allpatientsinthecontrolgroup receivedpalliativechemotherapy,indicatingadequategeneral conditionforantitumortreatment.MedianOSinthecontrol groupwas180days(6months)afterfirstdiagnosisofPC.In comparison,patientstreatedwithcatumaxomabhadasignificantsurvivalbenefit(log-rankp =0.0083),withahazardratio of0.421(95%confidenceinterval0.217-0.817)( fig.3) . Ströhlein/Lordick/Rüttinger/Grützner/ Schemanski/Jäger/Lindhofer/Hennig/ Jauch/Peschel/Heiss munecellsintheascitesfluidandsecondlyagainsttumorcells ontheperitonealsurface.Consequently,patientswithmalignantascitescouldpresumablyhaveadifferentordelayedpatternofadverseeventsafterintraperitonealtherapy.Actually, thisstudyproducedthesameMTDlevelwithoutanynewadverse events. In summary, intraperitoneal catumaxomab treatmentisnotlimitedtomalignantascitesbutcanbeperformed on patients with PC in an analogous way. This is of special interest as a randomized phase II/III study demonstrated the clinical efficacy of intraperitoneal catumaxomab treatment in patients with malignant ascites, resulting in approvalforclinicaltreatment [14] .
Catumaxomab contains xenogeneic protein and thus has thepotentialforimmunogenicity.Aftertherapy,7of11eval-uable patients developed moderate HAMA values, which were not related to the occurrence or severity of adverse events.Generally,theroleofHAMAdevelopmentafterantibody therapy remains unclear. High HAMA levels may inhibit antitumor cytotoxicity, but elevated HAMA levels did notinevitablyaffectsuccessfultherapy [23] andwereassociated with prolonged survival [24, 25] . In summary, the dose scheduleof10,20,50,and200mgadministeredondays0,3,7, and10wasregardedasafeasibleclinicalregimen.
Although clinical efficacy and survival were not primary studyendpoints,theresultsobtainedinpatientswithPCwere remarkable.AnalysisofEpCAM-positivetumorcellsinperitoneallavagesbeforeandaftertreatmentshowedasubstantialdecrease,suggestingperitonealtumorcellkilling.92%of allpatientsinthisstudyhadadvancedPC(GillyscoreofIII/ IV),representingpoorprognosticfeaturesatbaseline.Inthe matchedcontrolgroup,allpatientshadanadequategeneral condition to receive intravenous chemotherapy. Therefore, prolongedOSinthecatumaxomabgroupwasnotcausedby a selection bias favoring patients with good prognostic features. Theobservationthatnostudypatientdevelopedmalignant ascitesduringfollow-up,whichcouldbeexpectedin20-35%
Discussion
The results of this phase I/II study of the trifunctional antibodycatumaxomabdemonstratethatPCcanbetreatedsafely and effectively with 4 intraperitoneal infusions of catumaxomab. The MTD was reached at doses of 10, 20, 50, and 200mgadministeredondays0,3,7,and10,respectively.No patients required treatment in an intensive care unit and no treatment-relateddeathsoccurred.Duringandafterinfusions over 3 h, no substantial differences in tolerability were observed. The most common treatment-related adverse events attheMTDwerefever,vomiting,abdominalpain,skintoxicity, and nausea. These symptoms are typical of cytokine release and have been observed with several therapeutic antibodies [20, 21] .MeasurementsofIL-6andTNF-aconfirmed thefindingsofapilotstudythatthesecytokinesarereleased afterintraperitonealinfusionofcatumaxomab,eitherasaresult of systemic immune activation or a local inflammatory response [12] . However, as cytokine secretion by accessory cells is essential for the antitumor activity of catumaxomab, cytokinerelease-relatedsymptomsmayalsoreflectimmunologic efficacy. Another potential mechanism for causing adverse events is related to the anti-EpCAM-specific binding site. Elevations of liver function tests could be attributed to EpCAMexpressedontheepitheliumofthesmallbileducts [15] . On the other hand, the elevated liver parameters may alsobearesultofcytokinerelease [22] .Regardingindividual patients, a broad variety of cytokine levels and side effects wereseen.Therewasnoobservablecorrelationbetweenindividual responses to intraperitoneal catumaxomab and any clinicalorimmunologicalparameterbeforetherapy.Theadverse-eventprofilewasconsistentwiththatseenduringintraperitonealcatumaxomabtreatmentofpatientswithmalignant ascites [12, 17] StagingaccordingtoGillyetal. [18] :stageI:malignantgranulations<5mmingreatestdimension,localizedinonepartoftheabdomen;stageII:malignantgranulations<5mm,diffusetothewhole abdomen;stageIII:malignantgranulations5-2cm;stageIV:largemalignantcakes(>2cm).
